Tags

Type your tag names separated by a space and hit enter

Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Acta Neuropathol. 2019 10; 138(4):575-595.AN

Abstract

Parkinson's disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 1-120 α-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of α-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic nerve cell death starting from 6 and 12 months of age, respectively. In the MI2 mice, alterations in gait impairment can be detected by the DigiGait test from 9 months of age, while gross motor deficit was detected by rotarod test at 20 months of age when 50% of dopaminergic neurons in the substantia nigra pars compacta are lost. These changes were associated with an increase in the number and density of 20-500 nm α-synuclein species as shown by dSTORM. Treatment with the oligomer modulator anle138b, from 9 to 12 months of age, restored striatal dopamine release, prevented dopaminergic cell death and gait impairment. These effects were associated with a reduction of the inner density of large α-synuclein aggregates and an increase in dispersed small α-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progressive dopaminergic deficit observed in PD, showing that early synaptic dysfunction is associated to fine behavioral motor alterations, precedes dopaminergic axonal loss and neuronal death that become associated with a more consistent motor deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b's function in vivo supporting that targeting α-synuclein aggregation is a promising therapeutic approach for PD.

Authors+Show Affiliations

Department of Clinical Neurosciences, University of Cambridge, The Clifford Allbutt Building, Cambridge, CB2 0AH, UK.School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Sciences, Tel Aviv, Israel. Sagol School of Neuroscience, Tel Aviv University, 69978, Tel Aviv, Israel.Department of Clinical Neurosciences, University of Cambridge, The Clifford Allbutt Building, Cambridge, CB2 0AH, UK.Department of Clinical Neurosciences, University of Cambridge, The Clifford Allbutt Building, Cambridge, CB2 0AH, UK.Department of Clinical Neurosciences, University of Cambridge, The Clifford Allbutt Building, Cambridge, CB2 0AH, UK.Department of Psychology, University of Cambridge, Cambridge, CB2 3EB, UK.Max Planck Institute for Biophysical Chemistry, 37077, Göttingen, Germany. DFG Research Centre Nanoscale Microscopy and Molecular Physiology of the Brain, 37070, Göttingen, Germany.Max Planck Institute for Biophysical Chemistry, 37077, Göttingen, Germany. DFG Research Centre Nanoscale Microscopy and Molecular Physiology of the Brain, 37070, Göttingen, Germany.Center for Neuropathology and Prion Research, Ludwig Maximilians University Munich, 81377, Munich, Germany.Department of Psychology, University of Cambridge, Cambridge, CB2 3EB, UK. Department of Psychiatry, University of Cambridge, Cambridge, CB2 2SZ, UK.Max Planck Institute for Biophysical Chemistry, 37077, Göttingen, Germany. DFG Research Centre Nanoscale Microscopy and Molecular Physiology of the Brain, 37070, Göttingen, Germany. Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany.School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Sciences, Tel Aviv, Israel. Sagol School of Neuroscience, Tel Aviv University, 69978, Tel Aviv, Israel.Department of Clinical Neurosciences, University of Cambridge, The Clifford Allbutt Building, Cambridge, CB2 0AH, UK. mgs11@cam.ac.uk.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31165254

Citation

Wegrzynowicz, Michal, et al. "Depopulation of Dense Α-synuclein Aggregates Is Associated With Rescue of Dopamine Neuron Dysfunction and Death in a New Parkinson's Disease Model." Acta Neuropathologica, vol. 138, no. 4, 2019, pp. 575-595.
Wegrzynowicz M, Bar-On D, Calo' L, et al. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathol. 2019;138(4):575-595.
Wegrzynowicz, M., Bar-On, D., Calo', L., Anichtchik, O., Iovino, M., Xia, J., Ryazanov, S., Leonov, A., Giese, A., Dalley, J. W., Griesinger, C., Ashery, U., & Spillantini, M. G. (2019). Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathologica, 138(4), 575-595. https://doi.org/10.1007/s00401-019-02023-x
Wegrzynowicz M, et al. Depopulation of Dense Α-synuclein Aggregates Is Associated With Rescue of Dopamine Neuron Dysfunction and Death in a New Parkinson's Disease Model. Acta Neuropathol. 2019;138(4):575-595. PubMed PMID: 31165254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. AU - Wegrzynowicz,Michal, AU - Bar-On,Dana, AU - Calo',Laura, AU - Anichtchik,Oleg, AU - Iovino,Mariangela, AU - Xia,Jing, AU - Ryazanov,Sergey, AU - Leonov,Andrei, AU - Giese,Armin, AU - Dalley,Jeffrey W, AU - Griesinger,Christian, AU - Ashery,Uri, AU - Spillantini,Maria Grazia, Y1 - 2019/05/31/ PY - 2019/01/14/received PY - 2019/04/30/accepted PY - 2019/04/20/revised PY - 2019/6/6/pubmed PY - 2020/8/5/medline PY - 2019/6/6/entrez KW - Alpha-synuclein KW - Anle138b KW - Mouse model KW - Parkinson’s disease KW - Striatum KW - Substantia nigra KW - dSTORM SP - 575 EP - 595 JF - Acta neuropathologica JO - Acta Neuropathol VL - 138 IS - 4 N2 - Parkinson's disease (PD) is characterized by the presence of α-synuclein aggregates known as Lewy bodies and Lewy neurites, whose formation is linked to disease development. The causal relation between α-synuclein aggregates and PD is not well understood. We generated a new transgenic mouse line (MI2) expressing human, aggregation-prone truncated 1-120 α-synuclein under the control of the tyrosine hydroxylase promoter. MI2 mice exhibit progressive aggregation of α-synuclein in dopaminergic neurons of the substantia nigra pars compacta and their striatal terminals. This is associated with a progressive reduction of striatal dopamine release, reduced striatal innervation and significant nigral dopaminergic nerve cell death starting from 6 and 12 months of age, respectively. In the MI2 mice, alterations in gait impairment can be detected by the DigiGait test from 9 months of age, while gross motor deficit was detected by rotarod test at 20 months of age when 50% of dopaminergic neurons in the substantia nigra pars compacta are lost. These changes were associated with an increase in the number and density of 20-500 nm α-synuclein species as shown by dSTORM. Treatment with the oligomer modulator anle138b, from 9 to 12 months of age, restored striatal dopamine release, prevented dopaminergic cell death and gait impairment. These effects were associated with a reduction of the inner density of large α-synuclein aggregates and an increase in dispersed small α-synuclein species as revealed by dSTORM. The MI2 mouse model recapitulates the progressive dopaminergic deficit observed in PD, showing that early synaptic dysfunction is associated to fine behavioral motor alterations, precedes dopaminergic axonal loss and neuronal death that become associated with a more consistent motor deficit upon reaching a certain threshold. Our data also provide new mechanistic insight for the effect of anle138b's function in vivo supporting that targeting α-synuclein aggregation is a promising therapeutic approach for PD. SN - 1432-0533 UR - https://www.unboundmedicine.com/medline/citation/31165254/Depopulation_of_dense_α_synuclein_aggregates_is_associated_with_rescue_of_dopamine_neuron_dysfunction_and_death_in_a_new_Parkinson's_disease_model_ L2 - https://dx.doi.org/10.1007/s00401-019-02023-x DB - PRIME DP - Unbound Medicine ER -